Literature DB >> 33970096

Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report.

Minggui Pan1,2, Kristen Ganjoo3, Amer Karam4.   

Abstract

None: Patients with metastatic uterine leiomyosarcoma (uLMS) have poor prognosis due to limited treatment options, especially when disease progresses on doxorubicin and gemcitabine-docetaxel regimens. Here we report a patient whose metastatic uLMS contains a BRCA2 deep deletion as well as TP53 and PTEN deep deletion. The patient responded rapidly to olaparib, a poly (ADP-ribose) polymerase inhibitor, after progressing on gemcitabine-docetaxel, doxorubicin, and temozolomide regimens. This case report shall be helpful to the treatment of other patients with metastatic uLMS that harbors a BRCA2 mutation or deletion.
Copyright © 2021 The Permanente Press. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33970096      PMCID： PMC8784049          DOI： 10.7812/TPP/20.251

Source DB:  PubMed          Journal:  Perm J        ISSN： 1552-5767


  13 in total

1.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Authors:  George D Demetri; Margaret von Mehren; Robin L Jones; Martee L Hensley; Scott M Schuetze; Arthur Staddon; Mohammed Milhem; Anthony Elias; Kristen Ganjoo; Hussein Tawbi; Brian A Van Tine; Alexander Spira; Andrew Dean; Nushmia Z Khokhar; Youn Choi Park; Roland E Knoblauch; Trilok V Parekh; Robert G Maki; Shreyaskumar R Patel
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

2.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

3.  BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma.

Authors:  Nathan D Seligson; Esko A Kautto; Edward N Passen; Colin Stets; Amanda E Toland; Sherri Z Millis; Christian F Meyer; John L Hays; James L Chen
Journal:  Oncologist       Date:  2018-12-12

4.  Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Authors:  Martee L Hensley; John A Blessing; Robert Mannel; Peter G Rose
Journal:  Gynecol Oncol       Date:  2008-06       Impact factor: 5.482

5.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro
Journal:  N Engl J Med       Date:  2018-10-21       Impact factor: 91.245

6.  PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

Authors:  Konstantin J Dedes; Daniel Wetterskog; Ana M Mendes-Pereira; Rachael Natrajan; Maryou B Lambros; Felipe C Geyer; Radost Vatcheva; Kay Savage; Alan Mackay; Christopher J Lord; Alan Ashworth; Jorge S Reis-Filho
Journal:  Sci Transl Med       Date:  2010-10-13       Impact factor: 17.956

7.  Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.

Authors:  Martin D Forster; Konstantin J Dedes; Shahneen Sandhu; Sophia Frentzas; Rebecca Kristeleit; Alan Ashworth; Christopher J Poole; Britta Weigelt; Stan B Kaye; L Rhoda Molife
Journal:  Nat Rev Clin Oncol       Date:  2011-04-05       Impact factor: 66.675

Review 8.  The DNA damage response and cancer therapy.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

9.  Olaparib for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Johann de Bono; Joaquin Mateo; Karim Fizazi; Fred Saad; Neal Shore; Shahneen Sandhu; Kim N Chi; Oliver Sartor; Neeraj Agarwal; David Olmos; Antoine Thiery-Vuillemin; Przemyslaw Twardowski; Niven Mehra; Carsten Goessl; Jinyu Kang; Joseph Burgents; Wenting Wu; Alexander Kohlmann; Carrie A Adelman; Maha Hussain
Journal:  N Engl J Med       Date:  2020-04-28       Impact factor: 91.245

10.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504
View more
  3 in total

Review 1.  Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).

Authors:  Hiroshi Asano; Katsutoshi Oda; Kosuke Yoshihara; Yoichi M Ito; Noriomi Matsumura; Muneaki Shimada; Hidemichi Watari; Takayuki Enomoto
Journal:  J Gynecol Oncol       Date:  2022-05-03       Impact factor: 4.756

2.  Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas.

Authors:  Nathan D Seligson; Joy Tang; Dexter X Jin; Monica P Bennett; Julia A Elvin; Kiley Graim; John L Hays; Sherri Z Millis; Wayne O Miles; James L Chen
Journal:  NPJ Precis Oncol       Date:  2022-04-25

3.  Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation.

Authors:  Natalie Shammas; Tiffany Yang; Alireza Abidi; Malaika Amneus; Melissa Hodeib
Journal:  Gynecol Oncol Rep       Date:  2022-07-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.